Phase 1 N=38 Aldosterone and the Metabolic Syndrome
Metabolic Diseases · Diabetes Mellitus · Endocrine System Diseases
Primary: Plasma Insulin — 75.4; 50.1; 43.5; 114.0 uU/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=61 Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ADPKD
Primary: Change From Baseline in Flow Mediated Dilation at 6 Months. — -0.2; -0.4 Percent change.
Phase 4 N=90 Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN
Hypertension · Genetics Hypertension
Primary: Systolic /Diastolic Supine Morning Liberal Salt Automated Blood Pressure — 144.2; 148.5; 86.0; 91.4 mm hg — p=0.823
Phase 2 N=14 The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension
Hypertension
Primary: Muscle Sympathetic Nerve Activity at Rest — 41; 43.8 bursts/minute
Phase 2 N=15 Calcium Channel Blockade in Primary Aldosteronism
Primary Aldosteronism · Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Primary: Change in 24-hour Urinary Aldosterone Excretion Rate — 0.21 mcg/24h — p=0.96
Phase 4 N=79 Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial
Atherosclerosis
Primary: Percent Change in Atheroma Volume (PAV) in the Thoracic Aorta of Spironolactone vs. Placebo — 0.5; 7.3 percentage change — p=0.0293
N/A N=21 Hypoglycemia and the Mineralocorticoid Receptor
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
N/A N=92 Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Systemic Arterial Hypertension · Hypertension Resistant to Conventional Therapy · Myocardial Infarction
Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19
N/A N=38 Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
Obesity · Insulin Resistance
Primary: Change From Baseline in Post-ischemic Dilatation — 9.6; 10.2; -1.2; -2.0 percent dilalation
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
Phase 3 N=15 The Role of Mineralocorticoid Receptors in Vascular Function
Apparent Mineralocorticoid Excess (AME)
Primary: Forearm Blood Flow — 1.87; 1.34 ml/100ml of tissue/min
Phase 2 N=19 Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
Chronic Kidney Disease · Albuminuria
Primary: Difference in 24 Hour Ambulatory Systolic Blood Pressure — 7.7; 12.5 mm Hg
N/A N=7 Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate
Adrenal Insufficiency
Primary: Number of Participants With Adrenal Insufficiency — 7 participants
N/A N=69 Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease
Type 2 Diabetes Mellitus · Vascular Disease
Primary: Change in Coronary Flow Reserve From Baseline to 6 Months — 0.33; -0.10; 0.02 ratio
N/A N=155,963 Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene
Hypertension
Primary: Time to Dementia Onset — 12.6; 14.8; 20.9; 21.5 Incidence rate per 1000 person year
Phase 3 N=137 ENAC Blockade and Arterial Stiffness
Overweight and Obesity · Insulin Resistance
Primary: Carotid Femoral Pulse Wave Velocity — 7.25; 6.80; 7.12; 6.81 m/s
Phase 4 N=44 Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism
Metabolic Syndrome
Primary: Insulin Secretion — 293.1; 234.7; 330.8; 300.4 uU/mL*10min
Phase 3 N=20 Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
Heart Failure
Primary: Change in Body Weight — -1.9; -1.9 kilogram
Phase 4 N=16 Effect of Aldosterone on Energy Starvation in Heart Failure
Heart Failure · Nonischemic Dilated Cardiomyopathy
Primary: Left Ventricular Work-metabolic Index (WMI) at Baseline — 7.4 (x10^6), mL x mm Hg/m^2
Phase 2 N=8 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Phase 3 N=41 Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
Primary Hyperparathyroidism
Primary: Change in Parathyroid Hormone Levels — 4.0; -3.7; 0.8 pg/mL — p=0.84
Phase 1 N=30 Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects
Pharmacodynamic
Primary: Determination of the Ratio of Sodium to Potassium (Na/K) in Urine — 1.12929; 0.98207; 1.04238; 0.54902 log10(10*Na/K)
Phase 2 N=10 A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101 — 2…
Phase 2 N=35 DP13 - A Phase II Study in Patients With Primary Aldosteronism
Primary Aldosteronism
Primary: Change in Aldosterone-to-renin Ratio — -15.0; -7.0; -14.0; -11.8 ng*L/dL*mU — p=<0.0001
Phase 3 N=3,445 Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Cardiovascular Diseases · Heart Diseases · Heart Failure, Congestive
Primary: Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred First — 6.6; 5.9 Events…
Phase 2 N=6 AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy
Phelan-McDermid Syndrome · Epilepsy
Primary: Number of Adverse Events — 19 events
Phase 4 N=8 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
Mild Hypercortisolism
Primary: A1C Level — 6.2; 6.1375; 6.125 percentage of red blood cells
Phase 4 N=5 Adrenocorticotropic Hormone in Membranous Nephropathy
Membranous Nephropathy
Primary: Change in Proteinuria — 4.56; 1.36 ratio
Phase 2 N=59 Tissue Sodium in Pre-hypertensive Patients
Hypertension
Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L
N/A N=41 The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
Hyperparathyroidism
Primary: Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration — 70.9; 32.5 pg/mL — p=0.049